recombinant pigf 2 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
94
Structured Review
R&D Systems
recombinant pigf 2
Recombinant Pigf 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+pigf+2/Recombinant+Mouse+PlGF-2+Protein/pmc11275746__NIHPP2024__07__12__603312v1___supplement___1-9-7-12
Average 94 stars, based on 11 article reviews
Recombinant Pigf 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+pigf+2/Recombinant+Mouse+PlGF-2+Protein/pmc11275746__NIHPP2024__07__12__603312v1___supplement___1-9-7-12
Average 94 stars, based on 11 article reviews
recombinant pigf 2 - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
In Vivo:Article Title: Langerhans cells regulate immunity in adulthood by regulating postnatal dermal lymphatic development Article Snippet: For in vivo blocking experiments, PBS or Isotype control (5 ug/each ear, Invitrogen, #16-4301-85), anti-PIGF-2 (5 μg/each ear, R&D systems, #MAB465-500), anti-VEGFR1 (5 μg/each ear, R&D sysems, #MAB4711), antiVEGFR2 (5 μg/each ear, Bioxcell, #BE0060), and anti-VEGFR3 (5 μg/each ear, BioLegend, #140902) were injected daily into bilateral WT mice ears in various combinations using a Hamilton syringe (Hamilton, 10 ul gastight syringe #7653-01, 30-gauge needle #7803-07) from day 21 (3 weeks old) to day 35-42 (5~6 weeks old) for every day. .. For in vivo rescue experiments, PBS control, Article Title: Langerhans cells regulate immunity in adulthood by regulating postnatal dermal lymphatic development Article Snippet: For in vivo blocking experiments, PBS or Isotype control (5 ug/each ear, Invitrogen, #16-4301-85), anti-PIGF-2 (5 μg/each ear, R&D systems, #MAB465-500), anti-VEGFR1 (5 μg/each ear, R&D sysems, #MAB4711), anti-VEGFR2 (5 μg/each ear, Bioxcell, #BE0060), and anti-VEGFR3 (5 μg/each ear, BioLegend, #140902) were injected daily into bilateral WT mice ears in various combinations using a Hamilton syringe (Hamilton, 10 ul gastight syringe #7653-01, 30-gauge needle #7803-07) from day 21 (3 weeks old) to day 35-42 (5∼6 weeks old) for every day. .. For in vivo rescue experiments, PBS control, Control:Article Title: Langerhans cells regulate immunity in adulthood by regulating postnatal dermal lymphatic development Article Snippet: For in vivo blocking experiments, PBS or Isotype control (5 ug/each ear, Invitrogen, #16-4301-85), anti-PIGF-2 (5 μg/each ear, R&D systems, #MAB465-500), anti-VEGFR1 (5 μg/each ear, R&D sysems, #MAB4711), antiVEGFR2 (5 μg/each ear, Bioxcell, #BE0060), and anti-VEGFR3 (5 μg/each ear, BioLegend, #140902) were injected daily into bilateral WT mice ears in various combinations using a Hamilton syringe (Hamilton, 10 ul gastight syringe #7653-01, 30-gauge needle #7803-07) from day 21 (3 weeks old) to day 35-42 (5~6 weeks old) for every day. .. For in vivo rescue experiments, PBS control, Article Title: Langerhans cells regulate immunity in adulthood by regulating postnatal dermal lymphatic development Article Snippet: For in vivo blocking experiments, PBS or Isotype control (5 ug/each ear, Invitrogen, #16-4301-85), anti-PIGF-2 (5 μg/each ear, R&D systems, #MAB465-500), anti-VEGFR1 (5 μg/each ear, R&D sysems, #MAB4711), anti-VEGFR2 (5 μg/each ear, Bioxcell, #BE0060), and anti-VEGFR3 (5 μg/each ear, BioLegend, #140902) were injected daily into bilateral WT mice ears in various combinations using a Hamilton syringe (Hamilton, 10 ul gastight syringe #7653-01, 30-gauge needle #7803-07) from day 21 (3 weeks old) to day 35-42 (5∼6 weeks old) for every day. .. For in vivo rescue experiments, PBS control, Recombinant:Article Title: Langerhans cells regulate immunity in adulthood by regulating postnatal dermal lymphatic development Article Snippet: For in vivo blocking experiments, PBS or Isotype control (5 ug/each ear, Invitrogen, #16-4301-85), anti-PIGF-2 (5 μg/each ear, R&D systems, #MAB465-500), anti-VEGFR1 (5 μg/each ear, R&D sysems, #MAB4711), antiVEGFR2 (5 μg/each ear, Bioxcell, #BE0060), and anti-VEGFR3 (5 μg/each ear, BioLegend, #140902) were injected daily into bilateral WT mice ears in various combinations using a Hamilton syringe (Hamilton, 10 ul gastight syringe #7653-01, 30-gauge needle #7803-07) from day 21 (3 weeks old) to day 35-42 (5~6 weeks old) for every day. .. For in vivo rescue experiments, PBS control, Article Title: Langerhans cells regulate immunity in adulthood by regulating postnatal dermal lymphatic development Article Snippet: For in vivo blocking experiments, PBS or Isotype control (5 ug/each ear, Invitrogen, #16-4301-85), anti-PIGF-2 (5 μg/each ear, R&D systems, #MAB465-500), anti-VEGFR1 (5 μg/each ear, R&D sysems, #MAB4711), anti-VEGFR2 (5 μg/each ear, Bioxcell, #BE0060), and anti-VEGFR3 (5 μg/each ear, BioLegend, #140902) were injected daily into bilateral WT mice ears in various combinations using a Hamilton syringe (Hamilton, 10 ul gastight syringe #7653-01, 30-gauge needle #7803-07) from day 21 (3 weeks old) to day 35-42 (5∼6 weeks old) for every day. .. For in vivo rescue experiments, PBS control, Injection:Article Title: Langerhans cells regulate immunity in adulthood by regulating postnatal dermal lymphatic development Article Snippet: For in vivo blocking experiments, PBS or Isotype control (5 ug/each ear, Invitrogen, #16-4301-85), anti-PIGF-2 (5 μg/each ear, R&D systems, #MAB465-500), anti-VEGFR1 (5 μg/each ear, R&D sysems, #MAB4711), antiVEGFR2 (5 μg/each ear, Bioxcell, #BE0060), and anti-VEGFR3 (5 μg/each ear, BioLegend, #140902) were injected daily into bilateral WT mice ears in various combinations using a Hamilton syringe (Hamilton, 10 ul gastight syringe #7653-01, 30-gauge needle #7803-07) from day 21 (3 weeks old) to day 35-42 (5~6 weeks old) for every day. .. For in vivo rescue experiments, PBS control, Article Title: Langerhans cells regulate immunity in adulthood by regulating postnatal dermal lymphatic development Article Snippet: For in vivo blocking experiments, PBS or Isotype control (5 ug/each ear, Invitrogen, #16-4301-85), anti-PIGF-2 (5 μg/each ear, R&D systems, #MAB465-500), anti-VEGFR1 (5 μg/each ear, R&D sysems, #MAB4711), anti-VEGFR2 (5 μg/each ear, Bioxcell, #BE0060), and anti-VEGFR3 (5 μg/each ear, BioLegend, #140902) were injected daily into bilateral WT mice ears in various combinations using a Hamilton syringe (Hamilton, 10 ul gastight syringe #7653-01, 30-gauge needle #7803-07) from day 21 (3 weeks old) to day 35-42 (5∼6 weeks old) for every day. .. For in vivo rescue experiments, PBS control, |